In a move poised to advance domestic pharmaceutical production, Amyris, a leading synthetic biology company, has been awarded $12.3 million by the Administration for Strategic Preparedness and Response (ASPR). The funding, provided through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C), will support Amyris' innovative approach to pharmaceutical manufacturing, helping to address critical drug shortages in the United States.

Amyris plans to leverage its cutting-edge capabilities in organism engineering, precision fermentation, synthetic chemistry, and manufacturing expertise to develop up to three small-molecule drugs over the next two years. These drugs are part of the FDA's drug shortage list, highlighting their urgent need in the healthcare system.

The agreement with ASPR’s Center for Industrial Base Management and Supply Chain (IBMSC) will enable Amyris and its government partners to collaboratively determine which drug candidates to prioritize for production based on key technological milestones. Throughout the project, Amyris will also seek partnerships with GMP-certified manufacturers and explore pathways to bring these drugs to market.

“Amyris has consistently pushed the boundaries of what is possible in industrial biotechnology,” said Amyris CEO Kathy Fortmann. “With our strong focus on cutting-edge science and automation, this funding from IBMSC will accelerate our research and development efforts, bringing vital active pharmaceutical ingredients to market and delivering impactful healthcare solutions.”

The initiative is part of a broader effort by the U.S. government to strengthen the domestic pharmaceutical supply chain and reduce reliance on foreign production. The project has been funded in part by federal funds from the Department of Health and Human Services under the Other Transaction Authority Agreement #75A50123D00003.